Showing results (21-30 of 40) with videos related to
Sort By:
Pageof 4
European Urology|June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial CarcinomaPetros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-UpThomas Powles, Se Hoon Park, Claudia Caserta, et al.Cancer Science|December 29, 2019
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, et al.Nature Medicine|December 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trialThomas Powles, Srikala S Sridhar, Yohann Loriot, et al.The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 15, 2023
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trialMiguel Ángel Climent, Carlos Álvarez, Rafael Morales, et al.Pageof 4